N-(6-nitroveratryloxycarbonyl)-homocysteic acid cyanomethyl ester | 1085332-06-4

• 英文名称: N-(6-nitroveratryloxycarbonyl)-homocysteic acid cyanomethyl ester
• CAS: 1085332-06-4
• 化学式: C₁₆H₁₉N₃O₁₁S
• 分子量: 461.406
• InChiKey: WWQQWJZZMXVNBY-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.55
• 重原子数：
  31.0
• 可旋转键数：
  11.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  204.39
• 氢给体数：
  2.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  N-(6-nitroveratryloxycarbonyl)-homocysteic acid cyanomethyl ester 、 [(2R,3S,5R)-5-(4-氨基-2-氧代嘧啶-1-基)-2-(膦酰氧基甲基)四氢呋喃-3-基][(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基磷酸氢酯 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以13%的产率得到
  参考文献：
  名称：

  Synthesis of pdCpAs and transfer RNAs activated with derivatives of aspartic acid and cysteine

  摘要：

  Described herein is the preparation of new aminoacylated derivatives of the dinucleotide pdCpA, and of transfer RNAs. The focus of the present work is the synthesis of amino acid analogs related to aspartic acid and cysteine species that have important functional roles in many proteins. The activated aminoacyl-tRNAs prepared can be utilized for the elaboration of proteins containing modified aspartic acid and cysteine derivatives at predetermined sites. Of particular interest is definition of functional group protection strategies that can be used for the preparation of the aminoacylated pdCpAs and tRNAs. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.08.036
• 作为产物：
  描述：

  、 氯乙腈 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以150 mg的产率得到N-(6-nitroveratryloxycarbonyl)-homocysteic acid cyanomethyl ester
  参考文献：
  名称：

  Synthesis of pdCpAs and transfer RNAs activated with derivatives of aspartic acid and cysteine

  摘要：

  Described herein is the preparation of new aminoacylated derivatives of the dinucleotide pdCpA, and of transfer RNAs. The focus of the present work is the synthesis of amino acid analogs related to aspartic acid and cysteine species that have important functional roles in many proteins. The activated aminoacyl-tRNAs prepared can be utilized for the elaboration of proteins containing modified aspartic acid and cysteine derivatives at predetermined sites. Of particular interest is definition of functional group protection strategies that can be used for the preparation of the aminoacylated pdCpAs and tRNAs. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.08.036